Table 1 Baseline characteristics of study patients; by clopidogrel duration (9, 12, 15 months) analysis
9-months | 12-months | 15-months | |||||||
|---|---|---|---|---|---|---|---|---|---|
Discontinuous users (n = 292) | Continuous users (n = 452) | p* | Discontinuous users (n = 382) | Continuous users (n = 317) | p* | Discontinuous users (n = 489) | Continuous users (n = 164) | p* | |
Male | 237 (81.2%) | 350 (77.4%) | 0.22 | 306 (80.1%) | 248 (78.2%) | 0.54 | 386 (78.9%) | 131 (79.9%) | 0.79 |
Age (years) | 61.8 ± 12.0 | 63.1 ± 11.9 | 0.15 | 62.0 ± 12.3 | 63.3 ± 11.9 | 0.17 | 61.8 ± 11.7 | 64.2 ± 12.8 | 0.03* |
BMI (kg/m2) | 25.7 ± 3.8 | 25.5 ± 3.6 | 0.52 | 25.6 ± 3.7 | 25.6 ± 3.6 | 0.97 | 25.6 ± 3.7 | 25.7 ± 3.5 | 0.70 |
Current smokers | 102 (35.1%) | 128 (28.3%) | 0.05 | 131 (34.3%) | 90 (28.4%) | 0.09 | 162 (33.1%) | 43 (26.2%) | 0.10 |
Previous smokers | 56 (19.2%) | 84 (18.6%) | 0.82 | 72 (18.9%) | 57(18.0 %) | 0.77 | 91 (18.6%) | 30 (18.3%) | 0.93 |
Family history of CAD | 61 (20.9%) | 106 (23.5%) | 0.41 | 78 (20.4%) | 75 (23.7%) | 0.30 | 105 (21.5%) | 38 (23.2%) | 0.65 |
Clcr (mL/min) | 70.4 ± 25.4 | 68.8 ± 28.3 | 0.44 | 70.2 ± 26.1 | 68.6 ± 28.3 | 0.46 | 70.4 ± 26.2 | 66.9 ± 29.5 | 0.17 |
Cholesterol (mg/dL) | 180.8 ± 39.4 | 182.4 ± 39.9 | 0.60 | 181.1 ± 37.2 | 182.8 ± 42.4 | 0.60 | 181.8 ± 38.8 | 181.9 ± 40.8 | 0.98 |
TG (mg/dL) | 155.0 ± 98.4 | 146.2 ± 122 | 0.29 | 149.1 ± 95.0 | 150.0 ± 135 | 0.92 | 149.4 ± 118.8 | 149.5 ± 102 | 0.99 |
Glucose_AC (mg/dL) | 113.2 ± 37.0 | 114.7 ± 34.9 | 0.63 | 113.1 ± 34.9 | 115.2 ± 37.8 | 0.52 | 114.7 ± 37.6 | 111.9 ± 33.2 | 0.46 |
HbA1c (%) | 7.1 ± 2.2 | 7.0 ± 2.2 | 0.89 | 7.1 ± 2.2 | 6.7 ± 1.9 | 0.28 | 7.01 ± 2.0 | 6.48 ± 3.0 | 0.25 |
LVEF (%) | 57.3 ± 11.4 | 55.9 ± 8.5 | 0.35 | 56.5 ± 10.6 | 55.9 ± 8.7 | 0.68 | 56.4 ± 10.0 | 55.1 ± 7.4 | 0.44 |
Comorbidities | |||||||||
Diabetes mellitus (DM) | 89 (30.5%) | 143 (31.6%) | 0.74 | 117 (30.6%) | 100 (31.6%) | 0.79 | 152 (31.1%) | 54 (32.9%) | 0.66 |
Uncontrolled DM | 32 (11.0%) | 65 (14.4%) | 0.18 | 48 (12.6%) | 43 (13.6%) | 0.70 | 65 (13.3%) | 20 (12.2%) | 0.72 |
Hyperlipidemia | 130 (44.5%) | 219 (48.5%) | 0.29 | 175 (45.8%) | 154 (48.6%) | 0.47 | 229 (46.8%) | 79 (48.2%) | 0.77 |
Hypertension | 188 (64.6%) | 314 (69.6%) | 0.15 | 241 (63.3%) | 223 (70.6%) | 0.04* | 316 (64.9%) | 119 (72.6%) | 0.07 |
Heart failure | 14 (4.8%) | 21 (4.7%) | 0.93 | 21 (5.5%) | 12 (3.8%) | 0.29 | 19 (3.9%) | 10 (6.1%) | 0.23 |
Arrhythmia | 36 (12.3%) | 70 (15.5%) | 0.23 | 49 (12.9%) | 49 (15.5%) | 0.32 | 66 (13.5%) | 27 (16.5%) | 0.35 |
Cerebrovascular disease | 18 (6.2) | 21 (4.7) | 0.37 | 21 (5.5%) | 15 (4.8%) | 0.66 | 26 (5.3) | 9 (5.5) | 1.00 |
Peripheral vascular disease | 7 (2.4) | 3 (0.7) | 0.05 | 5 (1.3%) | 3 (1.0%) | 0.65 | 6 (1.2) | 2 (1.2) | 1.00 |
Chronic kidney disease | 12 (4.1%) | 26 (5.8%) | 0.32 | 16 (4.2%) | 20 (6.3%) | 0.21 | 24 (4.9%) | 9 (5.5%) | 0.84 |
End-stage renal disease | 5 (1.7%) | 7 (1.6%) | 1.00 | 6 (1.6%) | 4 (1.3%) | 0.73 | 6 (1.2%) | 4 (2.4%) | 0.28 |
GI ulcer/bleeding | 32 (11.0%) | 55 (12.2%) | 0.62 | 44 (11.5%) | 41 (12.9%) | 0.57 | 52 (10.6%) | 26 (15.9%) | 0.07 |
Anemia | 9 (3.1%) | 15 (3.3%) | 0.86 | 13 (3.4%) | 9 (2.8%) | 0.67 | 19 (3.9%) | 3 (1.8%) | 0.21 |
Co-medication | |||||||||
Aspirin | 254 (87.0) | 365 (80.8) | 0.03* | 334 (87.4) | 229 (72.2) | <.0001* | 433 (88.6) | 88 (53.7) | <.0001* |
ACEI/ ARB | 188 (64.4) | 310 (68.6) | 0.23 | 239 (62.6) | 220 (69.4) | 0.06 | 313 (64.0) | 110 (67.1) | 0.48 |
β-blocker | 187 (64.0) | 319 (70.6) | 0.06 | 233 (61.0) | 221 (69.7) | 0.02* | 303 (62.0) | 116 (70.7) | 0.04* |
Lipid-lowering agents | 189 (64.7) | 326 (72.1) | 0.03* | 251 (65.7) | 223 (70.4) | 0.19 | 319 (65.2) | 118 (72.0) | 0.11 |
Statin | 177 (60.6) | 313 (69.3) | 0.02* | 239 (62.6) | 212 (66.9) | 0.24 | 306 (62.6) | 110 (67.1) | 0.30 |
Warfarin | 6 (2.1) | 9 (2.0) | 1.00 | 5 (1.3) | 8 (2.5) | 0.27 | 8 (1.6) | 3 (1.8) | 1.00 |
CCB | 134 (45.9) | 198 (43.8) | 0.58 | 164 (42.9) | 136 (42.9) | 0.99 | 197 (40.3) | 75 (45.7) | 0.22 |
Nitrate | 140 (48.0) | 219 (48.5) | 0.89 | 163 (42.7) | 148 (46.7) | 0.29 | 195 (39.9) | 67 (40.9) | 0.83 |
NSAID | 28 (9.6) | 40 (8.9) | 0.73 | 33 (8.6) | 21 (6.6) | 0.32 | 29 (5.9) | 14 (8.5) | 0.24 |
COX-2 inhibitor | 20 (6.9) | 22 (4.9) | 0.25 | 24 (6.3) | 11 (3.5) | 0.09 | 19 (3.9) | 7 (4.3) | 0.82 |
Digoxin | 12 (4.1) | 14 (3.1) | 0.46 | 15 (3.9) | 10 (3.2) | 0.58 | 15 (3.1) | 7 (4.3) | 0.46 |
Diuretics | 71 (24.3) | 117 (25.9) | 0.63 | 93 (24.4) | 72 (22.7) | 0.61 | 103 (21.1) | 36 (22.0) | 0.81 |